NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ...

In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Pfizer Inc. faced a challenging day on the New York Stock Exchange, with its stock price dropping 2.1% to $29.57. Despite this setback, the pharmaceutical behemoth received positive news from a Phase ...

Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

Pfizer Inc.’s stock dipped 2.5% Thursday after two of its former executives said they would not support an effort by activist ...

Company also reports positive data from trial of combination treatment for a form of prostate cancer Pfizer Inc.'s stock dipped 2.5% Thursday after two of its former executives said they would not ...

Pfizer’s Talzenna-Xtandi combination has marked a major step forward in treating advanced prostate cancer, improving patient ...

US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...

The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...